SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the long-standing joke and the coin's presence on the Solana network. Community members are actively engaging in the 'What's UpDog?' meme, celebrating its resilience and unique place as the only UPDOG on the Jupiter Strict List.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates its short-term direction and potential to break key resistance levels, with some anticipating a surge towards new all-time highs. Bullish sentiment is fueled by expectations of a Q4 rally and institutional adoption, while others remain cautious, citing historical patterns and potential pullbacks. The conversation includes discussion of Bitcoin's role as a hedge against traditional financial systems and its correlation with altcoins and AI-related crypto.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" is trending with community members frequently repeating the phrase "crow with knife" and "caw caw". Discussion also highlights the token's presence across multiple chains and its deflationary burn mechanism. Community members are enthusiastic about its potential, with some calling it the only option.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its partnerships with major tech companies like AMD and Nvidia, particularly regarding QNX's role in automotive and robotics. Community members are highlighting the company's potential for growth and a possible breakout, fueled by anticipation for upcoming earnings. The conversation also includes discussions around technical analysis, market manipulation, and BlackBerry's long-term prospects as a software and cybersecurity player.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending as the crypto community discusses its potential role in AI, specifically how it could be linked with OpenAI and Sam Altman for proof of personhood. Community members are speculating on future price movements, while others are highlighting the integration of Worldcoin with various platforms and its increasing adoption for digital identity verification. Discussions also include the potential impact of new partnerships and technological advancements on Worldcoin's value.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as an AI meme coin linked to Elon Musk's Grok, sparking community excitement. The "Byte Army" is actively promoting the token, emphasizing its community-owned nature and potential in the AI and meme coin sectors. Discussions also highlight whale accumulation and positive sentiment from LunarCrush.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential revenue generation and real-world asset (RWA) adoption. Some users are speculating on partnerships and integrations with other projects. Bullish sentiment is fueled by discussions of on-chain matrix rewards and treasury mechanics.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its recent listing on Bifinance, generating excitement about increased liquidity and exposure. The community emphasizes its consistent 'grind,' utility development, and active developer, setting it apart from other meme coins. Many express bullish sentiment and highlight the project's commitment to delivering on promises, with some mentioning an upcoming burn event.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge ($CFG.X) is gaining attention, fueled by its focus on Real World Assets (RWAs) and recent integrations that facilitate easier tokenization and DeFi utilization. Community members highlight its potential to bridge traditional finance with DeFi, pointing to partnerships and new asset onboarding processes as catalysts. Discussions also revolve around technical analysis, potential price targets, and the impact of broader market trends.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending due to anticipation surrounding upcoming Phase 2b RSV drug results, sparking community discussion about its potential impact. Some are focused on technical levels to watch for momentum, while others are considering potential long-term gains. The broader context involves Enanta's pipeline and potential in the antiviral market.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Down 40% Year to Date: What Lies Ahead for the Stock? 

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects to advance a drug developed by Prothena into a late-stage study for ATTR amyloidosis with cardiomyopathy.On Stocktwits, retail sentiment around Prothena jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1332/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_1_09_34_PM_png_9facc97342.webp" alt="PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1332" height="122"><figcaption>PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for Prothena stock.<stembedurl>https://stocktwits.com/stocks271/message/623950128</stembedurl>Shares of Prothena traded 13% higher at the time of writing, while NYSE-listed shares of Novo traded 4% down.ATTR amyloidosis with cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease where misfolded transthyretin (TTR) proteins deposit in the heart muscle, leading to heart failure. Prothena-developed Coramitug is designed to deplete the abnormal protein deposits.Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. During Novo’s earnings call on Wednesday, the company said that it has successfully completed a mid-stage study of the drug and will now initiate a late-stage study during the course of 2025. The company also said that it will share detailed data from the mid-stage study at a medical conference later this year.Under the terms of the agreement between Prothena and Novo Nordisk, the former company is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones.Prothena is also eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the late-stage clinical trial. To date, Prothena has earned $100 million from the deal.PRTA stock is down by 43% this year and by about 61% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Equity

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.


Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well

RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.

AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? 

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD. 

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net cash burn from operating and investing activities to between $170 million and $178 million.&nbsp;The forecast follows a sweeping corporate restructuring that includes discontinuing development of birtamimab, an investigational therapy for AL amyloidosis, expected to reduce annual cash burn by about $96 million, and laying off 63% of its workforce.The biotech expects to end 2025 with roughly $298 million in cash, cash equivalents, and restricted cash at the midpoint.The revised cash burn outlook includes an estimated net loss of $240 million to $248 million, incorporating $36 million in non-cash share-based compensation and a $45 million non-cash tax expense related to deferred tax assets.The operating cost estimate includes $105 million to $110 million tied to birtamimab and reorganization-related expenses, such as severance and contract terminations.&nbsp;The company’s board and financial advisors are reviewing strategic options as it pivots to focus on its remaining pipeline and partnered programs.&nbsp;Prothena said it is reviewing strategic options as several clinical milestones approach, including Roche’s Phase 3 plans for prasinezumab in Parkinson’s, August data from Prothena’s PRX012 Alzheimer’s trial, and 2026 milestone payments of up to $105 million from partnered programs with Novo Nordisk and Bristol Myers Squibb.On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.One user expressed confidence in Prothena’s prospects, indicating the stock may have substantial upside potential and encouraging a broader, long-term perspective on its trajectory.<stembedurl>https://stocktwits.com/alromofi777/message/618389231</stembedurl>Another user said the cost and workforce reductions were largely anticipated, adding they plan to sell if shares hold above $6 on Friday following the recent rebound from lows.<stembedurl>https://stocktwits.com/SQUEAKSBANDIT/message/618364635</stembedurl>The stock has declined 57.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast

The biotech firm expects to end 2025 with nearly $300 million in cash as it pivots to focus on its Alzheimer’s and Parkinson’s pipeline.

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena Corporation plc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRTA News

PRTA Prothena Corporation plc